Cargando…

Disease burden of age-related macular degeneration in China from 1990 to 2019: findings from the global burden of disease study

BACKGROUND: To evaluate the disease burden of age–related macular degeneration (AMD) in terms of disability-adjusted life years (DALY) in China from 1990 to 2019. METHODS: Prevalence of blindness and vision loss due to AMD and DALY number, rate, and age-standardized rates of AMD were collected from...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yichi, Chen, Aiming, Zou, Minjie, Yang, Zhenlan, Zheng, Danying, Fan, Min, Jin, Guangming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Global Health 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564881/
https://www.ncbi.nlm.nih.gov/pubmed/34737869
http://dx.doi.org/10.7189/jogh.11.08009
_version_ 1784593702270795776
author Zhang, Yichi
Chen, Aiming
Zou, Minjie
Yang, Zhenlan
Zheng, Danying
Fan, Min
Jin, Guangming
author_facet Zhang, Yichi
Chen, Aiming
Zou, Minjie
Yang, Zhenlan
Zheng, Danying
Fan, Min
Jin, Guangming
author_sort Zhang, Yichi
collection PubMed
description BACKGROUND: To evaluate the disease burden of age–related macular degeneration (AMD) in terms of disability-adjusted life years (DALY) in China from 1990 to 2019. METHODS: Prevalence of blindness and vision loss due to AMD and DALY number, rate, and age-standardized rates of AMD were collected from the Global Burden of Disease Study 2019 database. The characters of variables were analyzed between China and its neighboring countries. RESULTS: From 1990 to 2019, the all-age number and rate for AMD prevalence and DALYs increased significantly in China, while the age standardized DALYs rate in 2019 showed a decrease of 3.63% compared with that in 1990. Females were found to have a higher prevalence and DALYs than males. The 65-69 age group had the highest AMD DALYs number, while the DALYs rate showed a positive association with age. In 2019, when compared to neighboring countries, the age standardized prevalence rate of AMD in China was ranked second after Pakistan, while the age standardized DALYs rate ranked second after Pakistan and India. CONCLUSIONS: Despite a small decrease in age standardized DALYs rate in China in the past three decades, the disease burden of AMD is still considerable and much higher compared to neighboring developed countries. Optimizing health services allocation is needed to further reduce this burden.
format Online
Article
Text
id pubmed-8564881
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher International Society of Global Health
record_format MEDLINE/PubMed
spelling pubmed-85648812021-11-03 Disease burden of age-related macular degeneration in China from 1990 to 2019: findings from the global burden of disease study Zhang, Yichi Chen, Aiming Zou, Minjie Yang, Zhenlan Zheng, Danying Fan, Min Jin, Guangming J Glob Health Research Theme 4: Health Transitions in China BACKGROUND: To evaluate the disease burden of age–related macular degeneration (AMD) in terms of disability-adjusted life years (DALY) in China from 1990 to 2019. METHODS: Prevalence of blindness and vision loss due to AMD and DALY number, rate, and age-standardized rates of AMD were collected from the Global Burden of Disease Study 2019 database. The characters of variables were analyzed between China and its neighboring countries. RESULTS: From 1990 to 2019, the all-age number and rate for AMD prevalence and DALYs increased significantly in China, while the age standardized DALYs rate in 2019 showed a decrease of 3.63% compared with that in 1990. Females were found to have a higher prevalence and DALYs than males. The 65-69 age group had the highest AMD DALYs number, while the DALYs rate showed a positive association with age. In 2019, when compared to neighboring countries, the age standardized prevalence rate of AMD in China was ranked second after Pakistan, while the age standardized DALYs rate ranked second after Pakistan and India. CONCLUSIONS: Despite a small decrease in age standardized DALYs rate in China in the past three decades, the disease burden of AMD is still considerable and much higher compared to neighboring developed countries. Optimizing health services allocation is needed to further reduce this burden. International Society of Global Health 2021-10-30 /pmc/articles/PMC8564881/ /pubmed/34737869 http://dx.doi.org/10.7189/jogh.11.08009 Text en Copyright © 2021 by the Journal of Global Health. All rights reserved. https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License.
spellingShingle Research Theme 4: Health Transitions in China
Zhang, Yichi
Chen, Aiming
Zou, Minjie
Yang, Zhenlan
Zheng, Danying
Fan, Min
Jin, Guangming
Disease burden of age-related macular degeneration in China from 1990 to 2019: findings from the global burden of disease study
title Disease burden of age-related macular degeneration in China from 1990 to 2019: findings from the global burden of disease study
title_full Disease burden of age-related macular degeneration in China from 1990 to 2019: findings from the global burden of disease study
title_fullStr Disease burden of age-related macular degeneration in China from 1990 to 2019: findings from the global burden of disease study
title_full_unstemmed Disease burden of age-related macular degeneration in China from 1990 to 2019: findings from the global burden of disease study
title_short Disease burden of age-related macular degeneration in China from 1990 to 2019: findings from the global burden of disease study
title_sort disease burden of age-related macular degeneration in china from 1990 to 2019: findings from the global burden of disease study
topic Research Theme 4: Health Transitions in China
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564881/
https://www.ncbi.nlm.nih.gov/pubmed/34737869
http://dx.doi.org/10.7189/jogh.11.08009
work_keys_str_mv AT zhangyichi diseaseburdenofagerelatedmaculardegenerationinchinafrom1990to2019findingsfromtheglobalburdenofdiseasestudy
AT chenaiming diseaseburdenofagerelatedmaculardegenerationinchinafrom1990to2019findingsfromtheglobalburdenofdiseasestudy
AT zouminjie diseaseburdenofagerelatedmaculardegenerationinchinafrom1990to2019findingsfromtheglobalburdenofdiseasestudy
AT yangzhenlan diseaseburdenofagerelatedmaculardegenerationinchinafrom1990to2019findingsfromtheglobalburdenofdiseasestudy
AT zhengdanying diseaseburdenofagerelatedmaculardegenerationinchinafrom1990to2019findingsfromtheglobalburdenofdiseasestudy
AT fanmin diseaseburdenofagerelatedmaculardegenerationinchinafrom1990to2019findingsfromtheglobalburdenofdiseasestudy
AT jinguangming diseaseburdenofagerelatedmaculardegenerationinchinafrom1990to2019findingsfromtheglobalburdenofdiseasestudy